Pfizer has started a global study to explore the efficacy and safety of an oral drug meant to prevent COVID-19, the disease caused by the CCP (Chinese Communist Party) virus. Pfizer’s Phase 2/3 study will evaluate the drug candidate in participants who live in the same household as a person who has a confirmed COVID-19 infection. Participants will also receive ritonavir, an antiretroviral typically used to treat HIV. The randomized, double-blind, and placebo-controlled study will enroll up to 2,660 healthy adults aged 18 or older, according to Pfizer. Half of the participants will be randomly assigned to receive the drug candidate and ritonavir, while the other half will get a placebo. Both groups will take either the drug or a placebo twice daily for five or 10 days. The primary objective of the study is to determine whether the drug is safe and whether it can prevent COVID-19 infection through 14 days …
RSS Feed | The Epoch Times